Shares of Cronos Group Inc. (NASDAQ:CRON – Get Free Report) have received an average rating of “Hold” from the five ratings firms that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $2.30.
CRON has been the subject of a number of analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Cronos Group in a report on Monday, December 29th. Canaccord Genuity Group initiated coverage on shares of Cronos Group in a report on Tuesday, January 27th. They set a “buy” rating for the company. TD Securities began coverage on shares of Cronos Group in a research note on Tuesday. They set a “buy” rating on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $2.30 price objective on shares of Cronos Group in a report on Wednesday, January 14th. Finally, Wall Street Zen raised Cronos Group from a “sell” rating to a “hold” rating in a report on Saturday, February 14th.
View Our Latest Research Report on Cronos Group
Institutional Trading of Cronos Group
Cronos Group Stock Up 1.3%
Shares of CRON stock opened at $2.68 on Tuesday. The company has a market cap of $1.02 billion, a P/E ratio of 26.99 and a beta of 0.80. Cronos Group has a 52 week low of $1.60 and a 52 week high of $3.43. The business has a 50 day moving average of $2.67 and a two-hundred day moving average of $2.60.
About Cronos Group
Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.
The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.
Recommended Stories
- Five stocks we like better than Cronos Group
- Elon’s Secret AI Partner?
- Elon Musk already made me a “wealthy man”
- Silver $500? The “Deficit Math” says it’s possible.
- Unlocked: Elon Musk’s Next Big IPO
- America’s 1776 happening again
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.
